Explore

Trendline Trendline
Co-Diagnostics to Present Co-Dx PCR Platform at ESCMID 2026, Aiming to Expand Global Reach

Co-Diagnostics to Present Co-Dx PCR Platform at ESCMID 2026, Aiming to Expand Global Reach

Co-Diagnostics to Present Co-Dx PCR Platform at ESCMID 2026, Aiming to Expand Global Reach
Rapid Read Rapid Read
Meiji Seika Pharma's Nacubactam to be Highlighted in ESCMID Global 2026 Presentations

Meiji Seika Pharma's Nacubactam to be Highlighted in ESCMID Global 2026 Presentations

Meiji Seika Pharma Co., Ltd. is set to present ten studies on its novel β-lactamase inhibitor nacubactam at the ESCMID Global 2026 conference. The presentations will include results from the Integral-2 Phase III clinical trial, which focuses on infections caused by carbapenem-resistant Enterobacterales (CRE). Carbapenem-resistant bacteria are a significant global threat, as carbapenems are often the last-resort treatment for severe infections. Meiji Seika Pharma has submitted an application for manufacturing and marketing approval of nacubactam in Japan, aiming to contribute to global efforts against antimicrobial resistance (AMR). The presentations will cover various aspects of nacubactam's efficacy and safety, including its combination with existing β-lactam antibiotics like cefepime and aztreonam.
Trendline Trendline
Cepheid and Oxford Nanopore Expand Partnership to Enhance Infectious Disease Research

Cepheid and Oxford Nanopore Expand Partnership to Enhance Infectious Disease Research

Cepheid and Oxford Nanopore Expand Partnership to Enhance Infectious Disease Research
Rapid Read Rapid Read
Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease

Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease

Bracco, a leader in diagnostic imaging, has expressed strong support for the American Society of Nuclear Cardiology's (ASNC) recent position statement. The ASNC recommends cardiac positron emission tomography (PET) with myocardial blood flow quantification as the preferred method for evaluating coronary artery disease (CAD). This endorsement is based on clinical evidence suggesting that cardiac PET offers superior diagnostic accuracy and risk assessment compared to SPECT imaging. Bracco has been a pioneer in this field since 1989, promoting the adoption of cardiac PET by improving access, reimbursement, and clinical education.
Trendline Trendline
Beckman Coulter Diagnostics Introduces Rapid Assay for Infection Differentiation

Beckman Coulter Diagnostics Introduces Rapid Assay for Infection Differentiation

Beckman Coulter Diagnostics Introduces Rapid Assay for Infection Differentiation
Rapid Read Rapid Read
Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease Diagnosis

Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease Diagnosis

Bracco, a leader in diagnostic imaging, has expressed strong support for the American Society of Nuclear Cardiology's (ASNC) recent position statement. The ASNC recommends cardiac positron emission tomography (PET) with myocardial blood flow quantification as the preferred method for evaluating coronary artery disease (CAD). This endorsement is based on evidence that cardiac PET offers superior diagnostic accuracy and risk assessment compared to SPECT imaging, particularly in complex cases or patients with obesity. Bracco has been a proponent of this approach since 1989, facilitating its adoption by improving access and reimbursement, and investing in provider education. The company's cardiac PET portfolio includes Cardiogen-82 and HeartSee, which aid in assessing coronary defects and disease severity.
Trendline Trendline
Beckman Coulter Diagnostics Introduces Rapid Bacterial vs. Viral Infection Test

Beckman Coulter Diagnostics Introduces Rapid Bacterial vs. Viral Infection Test

Beckman Coulter Diagnostics Introduces Rapid Bacterial vs. Viral Infection Test
Rapid Read Rapid Read
Study Reveals Unexpected Detection of Tuberculosis DNA in US-Born Patients

Study Reveals Unexpected Detection of Tuberculosis DNA in US-Born Patients

A recent study has uncovered an unexpectedly high prevalence of Mycobacterium tuberculosis DNA in respiratory samples from predominantly US-born patients hospitalized in Boston. The research, conducted over six years, utilized the 'Totally Optimized PCR (TOP) TB assay,' an ultrasensitive molecular assay, to detect TB-DNA in 12 to 16% of samples. This finding suggests a potential association between M. tuberculosis and various clinical syndromes in patients with a low pre-test probability of TB. The study highlights the need for more sensitive diagnostic tools to identify early stages of TB disease, as current methods may not detect low bacterial loads. The results, while preliminary, indicate a possible new variant of paucibacillary TB disease that remains unrecognized by existing diagnostic technologies.
Trendline Trendline
Johnson Johnson's Strategic Transformation in 2026

Johnson Johnson's Strategic Transformation in 2026

Johnson Johnson's Strategic Transformation in 2026
Trendline Trendline
AmacaThera's Non-Opioid Pain Relief Solutions Highlighted at LSX2026

AmacaThera's Non-Opioid Pain Relief Solutions Highlighted at LSX2026

AmacaThera's Non-Opioid Pain Relief Solutions Highlighted at LSX2026
Trendline Trendline
FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion

FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion

FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion
Rapid Read Rapid Read
ACT Project Launches Survey to Enhance AMR Awareness Among Food Producers

ACT Project Launches Survey to Enhance AMR Awareness Among Food Producers

The Action to support implementation of Codex AMR texts (ACT) project has released two survey templates aimed at increasing awareness of antimicrobial resistance (AMR) among food producers. These surveys, available in English and Spanish, target animal producers, veterinarians, plant producers, and technicians to assess their understanding of AMR issues. Developed by the ACT Regional Team in Latin America, with input from Bolivia's SENASAG and Colombia's ICA, the surveys have been successfully implemented in Bolivia and Colombia. The initiative seeks to guide communication strategies and training efforts to reduce antimicrobial use in food production, addressing AMR as a global health threat.